American Bio Medica Corporation
ABMC
$0.00
$0.000.00%
OTC PK
| 03/31/2023 | 12/31/2022 | 09/30/2022 | 06/30/2022 | 03/31/2022 | |
|---|---|---|---|---|---|
| Revenue | -63.80% | -58.88% | -49.56% | -39.78% | -49.72% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -63.80% | -58.88% | -49.56% | -39.78% | -49.72% |
| Cost of Revenue | -42.98% | -33.73% | -35.25% | -31.87% | -45.94% |
| Gross Profit | -131.36% | -135.34% | -89.48% | -62.75% | -59.03% |
| SG&A Expenses | -29.70% | -35.89% | -33.74% | -26.46% | -28.28% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -35.49% | -33.94% | -33.55% | -28.66% | -37.96% |
| Operating Income | -21.18% | -12.98% | -1.04% | 1.25% | -16.67% |
| Income Before Tax | 400.00% | -205.42% | -283.74% | 64.77% | 72.27% |
| Income Tax Expenses | 0.00% | 0.00% | 0.00% | -50.00% | 0.00% |
| Earnings from Continuing Operations | 397.20% | -204.54% | -282.21% | 64.72% | 72.12% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 397.20% | -204.54% | -282.21% | 64.72% | 72.12% |
| EBIT | -21.18% | -12.98% | -1.04% | 1.25% | -16.67% |
| EBITDA | -24.41% | -15.30% | -2.88% | -0.19% | -20.10% |
| EPS Basic | 461.22% | -159.29% | -148.28% | 77.98% | 82.05% |
| Normalized Basic EPS | -148.48% | -75.24% | -42.02% | 60.10% | 61.18% |
| EPS Diluted | 208.99% | -143.79% | -117.95% | 75.75% | 67.40% |
| Normalized Diluted EPS | -148.48% | -75.24% | -42.02% | 60.10% | 61.18% |
| Average Basic Shares Outstanding | 3.47% | 8.49% | 23.06% | 26.90% | 26.40% |
| Average Diluted Shares Outstanding | 3.47% | 8.49% | 23.06% | 26.90% | 26.40% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |